Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CardioCell (Wharton's jelly MSCs) for critical limb ischemia without revascularization options
2016-004684-40Phase 2Completed
- Sponsor
- Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Start
- Jan 2018
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ischemia-tolerant mesenchymal stem cells in chronic limb-threatening ischemia (CLTI), sponsored by Krakowski Szpital Specjalistyczny im. Jana Pawła II. Started Jan 2018; status: completed.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2016-004684-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004684-40.